Intraoperative Detection of Residual Cancer in Breast Cancer

Breast Cancer Clinical Trial

Official title:

Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03321929
• Other study ID #: CL0006
• Secondary ID: 5R44CA211013-02
• Status: Completed
• Phase: Phase 2
• Start date: February 6, 2018
• Est. completion date: April 10, 2020

Study information

• Verified date: January 2023
• Source: Lumicell, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM imaging device), in identifying residual cancer in the tumor bed of female breast cancer patients. During the study, study physicians and clinical staff will complete hands-on training in anticipation of the upcoming pivotal study. Site-specific or user-specific issues related to the use of the device will be identified and addressed. Additionally, the data collected in the study will be used to continue training the tumor detection algorithm of the device.

In this study, patients will be injected with LUM015 prior to surgery. The study physicians will perform lumpectomy procedures according to his or her institution's standard of care practice. After the main specimen removal is completed, the study physician will use the LUM Imaging Device to image the tumor bed. Therapeutic shaves will be removed based on the recommendation of the LUM Imaging System. Patients will be followed until their first standard of care post-operative follow-up visit.

Description:

For breast cancer lumpectomies, the presence of residual cancer cells left in the tumor bed after initial resection in inferred by post-operative margin assessment of the resected tissue by a pathologist.

Phase C enrollment will include approximately 5 patients per surgeon, with 2-3 surgeons per site and up to 20 sites. Subjects undergoing a lumpectomy procedure to treat primary breast cancer will be injected with a single dose of LUM015 4 ± 2 hours prior to surgery at a dose of 1.0 mg/kg. The sequence of events during the surgical procedure will vary based on the standard of care used by the surgeon. Patients will receive at a minimum the standard of care practices for each site. Lumicell-guided shaved cavity margins will be removed after the surgeon has attempted to remove the main specimen with grossly negative margins.

Study treatment ends when the surgery is completed. All patients will continue their enrollment in the study until their first follow-up visit and they will continue to be followed until the medical team determines no further surgical intervention is required. Patients with adverse events that are determined to be possibly related to the LUM Imaging System will be followed until resolution or stabilization of the adverse event.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 234
• Est. completion date: April 10, 2020
• Est. primary completion date: April 10, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Subjects must have histologically or cytologically confirmed primary invasive breast cancer, ductal carcinoma in situ (DCIS) or a combination of invasive breast cancer and DCIS. The protocol accepted methods for obtaining the histological samples are diagnostic core needle biopsies or fine needle biopsies.

• Female, age of 18 years or older. Because no dosing or adverse event data are currently available on the use of LUM015 in subjects <18 years of age, children are excluded from this study.

• Subjects must be scheduled for a lumpectomy for a breast malignancy.

• Subjects must be able and willing to follow study procedures and instructions.

• Subjects must have received and signed an informed consent form.

• Subjects must have no uncontrolled serious medical problems except for the diagnosis of cancer, as per the exclusion criteria listed below.

• Subjects must have normal organ and marrow function within limits as defined below:

• Leukocytes > 3,000/mcL

• Platelets > 75,000/mcL

• total bilirubin within normal institutional limits

• AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal

• Creatinine = 1.5 mg/dL or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.

Exclusion criteria:

• Subjects who are treated for bilateral breast cancer resection procedure.

• Subjects who are pregnant at the time of diagnosis of their breast cancer; this exclusion is necessary because the teratogenic properties of LUM015 are unknown. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with LUM015, breastfeeding should be discontinued if the mother is treated with LUM015.

• Subjects who are sexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Breast cancer patients are routinely advised against becoming pregnant during treatment, so this requirement does not differ from standard of care.

• Subjects who have taken an investigational drug within 30 days of enrollment.

• Subjects with prolonged QTc interval defined as greater than 480 ms.

• Subjects who will have administration of methylene blue or any dye for sentinel lymph node mapping on the day of the surgery prior to imaging the lumpectomy cavity with the LUM Imaging Device.

• Subjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents.

• Subjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known HTN should be stable within these ranges while under pharmaceutical therapy.

• History of allergic reaction attributed to drugs containing polyethylene glycol (PEG).

• History of allergic reaction to any oral or intravenous contrast agents.

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.

• HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with LUM015.

• Any subject for whom the investigator feels participation is not in the best interest of the subject.

• Subjects undergoing a second lumpectomy procedure because of positive margins in a previous surgery prior to entering this study.

• Subjects with prior ipsilateral breast cancer surgeries, mastectomies, breast reconstructions or implants.

• Subjects who have undergone a surgical biopsy for any reason in the ipsilateral breast performed less than 2 years prior to enrollment of this study.

• Subjects with prior ipsilateral reduction mammoplasties (breast reductions) performed less than 2 years prior to enrollment to this study.

• Subjects previously treated with systemic therapies to treat the cancer to be removed during this clinical investigation, such as neo-adjuvant chemotherapy or hormonal therapy.

• Subjects undergoing breast conserving surgery whose resected specimen will be evaluated with frozen section.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Neoplasm, Residual

Intervention

Combination Product:
• LUM Imaging System
Drug: LUM015 Device: LUM 2.6 Imaging Device

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Lahey Hospital and Medical Center	Burlington	Massachusetts
United States	Comprehensive Breast Care Center	Clearwater	Florida
United States	Cleveland Clinic	Cleveland	Ohio
United States	Dallas Breast Center	Dallas	Texas
United States	Duke University Medical Center	Durham	North Carolina
United States	Penn State Hershey Medical Center	Hershey	Pennsylvania
United States	MD Anderson Cancer Center	Houston	Texas
United States	Baptist MD Anderson Cancer Physicians	Jacksonville	Florida
United States	University of South Alabama	Mobile	Alabama
United States	Yale University School of Medicine	New Haven	Connecticut
United States	Stanford University Medical Center	Palo Alto	California
United States	Beaumont Royal Oak	Royal Oak	Michigan
United States	Franciscan Breast Surgery	Tacoma	Washington
United States	Beaumont Troy	Troy	Michigan
United States	Novant Health	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Lumicell, Inc.	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Surgeons Trained on the Use of the LUM Imaging System	Surgeons were trained on using the LUM Imaging System in preparation for participating in future clinical trials with the LUM Imaging System. Workflows were established at each institution to support the use of the LUM Imaging System and protocol adherence during lumpectomy procedures. Surgeons were not participants in the trial. Surgeons were the Investigators in the trial.	1 day
Primary	Collect Data to Refine and Verify the Tumor Detection Algorithm.	Data were collected from mITT population, which included all the patients imaged with the LUM Imaging System.; This metric measured the residual cancer that current Standard of Care (SOC) lumpectomy failed to remove.; It was defined as among all the patients, the percentage of subjects who had residual cancer found in at least one LUM-guided shave (therapeutic shave or "T-shave") after the current initial SOC lumpectomy procedure was completed.	1 day
Secondary	Number of Patients With Reported Adverse Events	Reported adverse events will be assessed and aggregated according to event type, relation to device or drug, and severity.	Patients were evaluated for adverse events from time of injection until standard post-surgery follow-up visit (Median 31 days after lumpectomy).
Secondary	Tumor Removal Rate in the Whole mITT Population by SOC Margin Status	Collect data to verify the detection algorithm reported in previous studies by SOC margin status	1 week
Secondary	Tumor Removal Rate Within Subjects Having Positive Standard of Care Margins	Tumor removal rate was measured as the percentage of the subjects who had residual tumor removed guided by Lumicell Imaging System after standard of care (SOC) procedure within subjects who had positive margins after SOC.	1 Week
Secondary	Tumor Removal Rate Within Subjects Having All Negative SOC Margins	Tumor removal rate was measured as the percentage of the subjects who had residual tumor removed guided by Lumicell Imaging System after standard of care (SOC) procedure within subjects who had negative margins after SOC.	1 Week
Secondary	Sensitivity and Specificity of the LUM Imaging System in Predicting Residual Cancer in the Cavity	Sensitivity and specificity were measured at the tissue level for the Lumicell imaging signal for the sensitivity and specificity on the residual tumor in the cavity of corresponding orientations after standard of care (SOC) of Lumpectomy. Generalized Estimating Equation (GEE) has been applied using generalized linear model having binomial link function and compound symmetry working correlation structure within each subject.	1 Week
Secondary	Detection and Conversion of Positive Margins in Subjects After BCS SOC	Conversion was measured as the ratio of the subjects having all the positive margins after BCS SOC converted to negatives after Lumicell Imaging guided procedure.; Detection was measured as the ratio of the subjects having all or at least one positive margin after BCS SOC detected by Lumicell Imaging System.; BCS: Breast-conserving surgery; SOC: Standard of Care	1 Week
Secondary	Volume of Therapeutic Shaves Removed During Lumpectomy.	The median volumes of Lumicell Imaging System - guided shaves (therapeutic shaves) were measured and the median total volume removed during lumpectomy was presented as well.	1 Week
Secondary	Contribution of Therapeutic Shaves to Total Volume Removed During Lumpectomy.	The contribution of the volumes of Lumicell Imaging System - guided shaves (therapeutic shaves) were measured as percentage of the sum of the volumes of the therapeutic shaves out of the total volume removed during lumpectomy.	1 Week